Intermittent fasting study protocol may reduce hypos

The first study to taper hypoglycaemic drug levels for patients with type 2 diabetes who are on an intermittent fasting regimen has shown lower than expected hypoglycaemic events.

Designed to see whether people with type 2 diabetes on glucose-lowering medications could safely implement the popular 5:2 intermittent fasting diet, where food intake is calorie-restricted just two days a week, the New Zealand study enrolled 37 patients.

Despite reducing glucose-lowering drugs on fasting days, hypoglycaemic events were twice as likely on days when just 2092-2510kJ were